RebmAb 200
Alternative Names: RebmAb-200Latest Information Update: 03 Mar 2023
At a glance
- Originator Recepta biopharma
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Type IIb sodium-phosphate cotransporter protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 11 Jan 2023 RebmAb licensed to Mersana Therapeutics (Receta biopharma Pipeline, October 2015)
- 20 Oct 2015 Preclinical trials in Cancer in Brazil (Parenteral) (Recepta biopharma Pipeline, October 2015)